Skip to main content
L

Lionco Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 603669 ISIN · CNE1000022R8 LEI · 300300EU7LBPZ25TZO93 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,202 across all filing types
Latest filing 2021-08-11 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 603669

About Lionco Pharmaceutical Group Co.,Ltd.

Lionco Pharmaceutical Group Co., Ltd. is a pharmaceutical enterprise focused on the research, development, production, and sale of chemical drug preparations. The company specializes in a diverse range of therapeutic areas, including anti-infectives, digestive system treatments, cardiovascular health, and respiratory medicine. Its product portfolio primarily consists of high-end generic drugs, featuring formulations such as freeze-dried powder for injection, small-volume injections, and solid oral dosages. Lionco emphasizes technological innovation and quality control to provide clinical solutions for various medical conditions. The group operates multiple manufacturing facilities and maintains a comprehensive distribution network to serve healthcare providers and patients.

Recent filings

Filing Released Lang Actions
第三届董事会第十四次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at a board meeting of Lingkang Pharmaceutical Group Co., Ltd. It details the convening of the third board's 14th meeting, voting results on specific proposals including a related-party transaction and the calling of an extraordinary general meeting. The content focuses on board decisions and procedural compliance, with no financial statements or detailed financial data presented. The document length is short (990 characters), and it is clearly a board meeting resolution announcement rather than a full report or financial disclosure. Therefore, it fits best under the category of Board/Management Information (MANG).
2021-08-11 Chinese
独立董事关于公司第三届董事会第十四次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion from the independent directors of Lingkang Pharmaceutical Group Co., Ltd. regarding a specific board meeting held on August 11, 2021. It discusses the fairness and compliance of a related-party transaction approved at the board meeting. The content focuses on governance and board oversight rather than financial results or audit findings. It does not contain financial statements or earnings data, nor is it a general announcement or certification. This fits the category of Board/Management Information (MANG), which covers announcements related to board decisions and management matters.
2021-08-11 Chinese
独立董事关于公司第三届董事会第十四次会议相关事项的事前认可意见
Board/Management Information Classification · 95% confidence The document is a formal opinion from independent directors regarding a specific agenda item for an upcoming board meeting, specifically about an affiliated transaction contract. It references regulatory guidelines for independent directors and corporate governance but does not contain financial statements or results. The document is short (506 characters) and is a pre-approval opinion related to board meeting matters, not a full report or announcement of voting results. This fits best under Board/Management Information (MANG), which covers announcements related to board activities and management decisions.
2021-08-11 Chinese
关于公司全资子公司签订《成都上锦南府医院药品、试剂、医用耗材等物资供应与配送长期服务合同》暨关联交易的公告
Regulatory Filings Classification · 95% confidence The document is an announcement by Lingkang Pharmaceutical Group Co., Ltd. regarding a long-term service contract signed by its wholly-owned subsidiary with Chengdu Shangjin Nanfu Hospital. It details the contract terms, related party relationships, board and supervisory approvals, independent directors' opinions, and risk disclosures. The document is a formal disclosure of a related-party transaction requiring shareholder approval, consistent with regulatory requirements for listed companies. It does not contain financial statements, audit opinions, earnings data, or management discussion of financial results. It is not a report but an announcement of a corporate transaction and related governance procedures. Therefore, it fits best under the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance disclosures that do not fit other specific categories.
2021-08-11 Chinese
第三届监事会第十三次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of a resolution passed at the 13th meeting of the third Supervisory Board of Lingkang Pharmaceutical Group Co., Ltd. It details the meeting's convening, attendance, and the approval of a proposal related to a subsidiary's contract and related party transaction. There is no financial data, no mention of annual or quarterly reports, no voting results from a general meeting, and no indication of a report publication or regulatory filing. The content is about board-level decision-making and internal governance matters. Therefore, it fits best under Board/Management Information (MANG). The document length is short and focused on management decisions rather than financial or regulatory reporting.
2021-08-11 Chinese
关于使用闲置募集资金购买理财产品到期收回及继续购买理财产品的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Lingkang Pharmaceutical Group Co., Ltd. regarding the use of idle raised funds to purchase financial products, including details of the amounts, products, expected returns, risk control measures, and approvals by the board and supervisory committee. It references prior announcements and approvals related to the use of raised funds for cash management. The document is about the company's cash management activities using idle raised funds, specifically purchasing and redeeming financial products, and does not contain comprehensive financial statements or detailed financial performance data. It is a regulatory announcement about capital management activities rather than a full financial report or earnings release. The document length is 4584 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, the most appropriate classification is Capital/Financing Update (CAP), as it updates on the company's financing activities related to the use of raised funds for financial products.
2021-07-26 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.